Progesterone and hair loss is a topic of growing interest, particularly among women navigating hormonal changes during perimenopause, postpartum recovery, or whilst using hormonal contraception or HRT. Progesterone is a key steroid hormone involved in the menstrual cycle and pregnancy, and its fluctuating levels may influence hair follicle behaviour — though the clinical evidence in humans remains limited. This article explores how progesterone affects hair growth, the common hormonal causes of hair loss in women, treatment risks, and when to seek medical advice in line with NHS and NICE guidance.

How Progesterone Affects Hair Growth and Loss

Progesterone may theoretically help maintain hair in the growth phase by inhibiting DHT production, but this mechanism has not been confirmed in robust human clinical trials and any hair-protective effect remains theoretical.

Progesterone is a naturally occurring steroid hormone produced primarily by the ovaries following ovulation, and in smaller amounts by the adrenal glands. It plays a central role in the menstrual cycle, pregnancy, and the regulation of other sex hormones. Its relationship with hair growth is complex and not yet fully understood; current human clinical evidence remains limited.

Hair growth occurs in three phases: anagen (active growth), catagen (transition), and telogen (resting and shedding). It has been proposed — largely on the basis of in vitro and animal studies — that progesterone may help maintain hair in the anagen phase by inhibiting the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT). DHT is a potent androgen associated with miniaturisation of hair follicles, particularly in individuals with a genetic predisposition to androgenetic alopecia. However, whether this mechanism operates in a clinically meaningful way in human scalp hair has not been established in robust clinical trials, and any hair-protective effect of progesterone should be regarded as theoretical at present.

Progesterone levels fluctuate significantly throughout the menstrual cycle, during perimenopause, and after childbirth. Postpartum telogen effluvium — a form of diffuse hair shedding that commonly occurs two to four months after delivery — is primarily driven by the sharp fall in oestrogen that follows birth; progesterone withdrawal may be a contributing factor, though the relative contribution of each hormone is not clearly defined. Similarly, during the menopausal transition, declining oestrogen is considered the principal hormonal driver of hair follicle changes, with falling progesterone as a possible additional factor.

Synthetic progestogens (progestins), used in hormonal contraceptives and some hormone replacement therapy (HRT) formulations, behave differently from natural progesterone. Some progestins have androgenic activity and may contribute to hair thinning in susceptible individuals; however, the effect is patient-specific and depends on the individual molecule, dose, and the person's androgen sensitivity. Changes in sex hormone-binding globulin (SHBG) levels — which affect the availability of free androgens — also play a role in contraceptive-related hair changes. Micronised progesterone, the bioidentical form used in some HRT regimens, is considered to have a more neutral androgenic profile than certain synthetic progestogens, though evidence that it specifically benefits hair is limited and not confirmed by large-scale clinical trials.

Common Causes of Hormonal Hair Loss in Women

Hormonal hair loss in women is most commonly caused by androgenetic alopecia, telogen effluvium, PCOS, thyroid dysfunction, or menopausal oestrogen decline — rarely by progesterone imbalance alone.

Not sure if this is normal? Chat with one of our pharmacists →

Hormonal hair loss in women is far more common than is often acknowledged, and progesterone imbalance is just one of several potential contributing factors. Understanding the broader hormonal landscape is essential for accurate diagnosis and effective management.

Key hormonal causes of hair loss in women include:

• Androgenetic alopecia (female pattern hair loss): Driven by genetic sensitivity to androgens, particularly DHT. It typically presents as diffuse thinning over the crown and widening of the central parting, rather than the receding hairline seen in men.

• Telogen effluvium: A reactive, often temporary shedding triggered by hormonal shifts such as postpartum oestrogen withdrawal, stopping the combined oral contraceptive pill, or the onset of perimenopause.

• Polycystic ovary syndrome (PCOS): Characterised by elevated androgens, irregular cycles, and insulin resistance. Hair thinning on the scalp alongside increased facial or body hair (hirsutism) is a common presentation.

• Thyroid dysfunction: Both hypothyroidism and hyperthyroidism can cause diffuse hair loss. Testing should be guided by clinical history and examination in line with UK primary care pathways, rather than performed routinely in all cases.

• Menopause and perimenopause: The decline in oestrogen during this transition reduces the protective effect this hormone has on hair follicles, often accelerating androgenetic alopecia; falling progesterone may be an additional contributing factor.

Red-flag features requiring prompt or urgent medical assessment include:

• Scalp pain, tenderness, erythema, scaling, pustules, or areas of scarring or atrophy — these may indicate a scarring (cicatricial) alopecia, which requires early specialist assessment to prevent permanent follicle loss

• Rapid or patchy hair loss with associated systemic illness

• Signs of virilisation — such as deepening of the voice, clitoromegaly, or severe acne — which may indicate an androgen-secreting tumour and warrant urgent investigation

Hair loss in women is rarely caused by a single hormone in isolation. Oestrogen, progesterone, androgens, thyroid hormones, cortisol, and insulin all interact within a complex endocrine network. A thorough clinical assessment — including a detailed menstrual and medical history, alongside targeted investigations — is necessary before attributing hair loss to any one hormonal cause. Self-diagnosing or self-treating hormonal hair loss without professional guidance is not recommended.

Worried about interactions with other medications? Speak to one of our pharmacists →

Risks and Side Effects of Progesterone Treatment in the UK

Progesterone treatment can cause drowsiness, breast tenderness, mood changes, and irregular bleeding; some synthetic progestogens may worsen hair thinning due to their androgenic activity.

In the UK, progesterone is used therapeutically in several contexts, including as part of HRT for menopausal women, in fertility treatment, and to support the luteal phase in assisted reproduction. The most commonly prescribed form is micronised progesterone, which is licensed by the Medicines and Healthcare products Regulatory Agency (MHRA). Observational evidence and some comparative data suggest it may have a more favourable tolerability profile than certain older synthetic progestogens for some outcomes, though this varies by outcome measured (for example, venous thromboembolism risk and breast effects), and women should discuss the options with their prescriber.

Whilst some women report improvements in hair quality when starting progesterone as part of HRT — particularly if they were previously progesterone-deficient — others notice increased shedding, especially in the initial weeks of treatment. This may reflect a temporary adjustment in the hair cycle as hormone levels stabilise. There is no robust clinical evidence from large-scale trials confirming that progesterone supplementation reliably treats or reverses hair loss.

Recognised side effects of progesterone treatment include:

• Drowsiness or dizziness (oral micronised progesterone should be taken at night for this reason)

• Headache

• Breast tenderness

• Mood changes, including low mood or anxiety in some individuals

• Irregular vaginal bleeding or spotting, especially in the early months of HRT

• Nausea or abdominal discomfort

For a full list of side effects and contraindications, refer to the Summary of Product Characteristics (SmPC) for the specific product, available via the Electronic Medicines Compendium (EMC).

Some synthetic progestogens used in combined contraceptive pills — such as levonorgestrel or norethisterone — have androgenic activity and may worsen hair thinning in women who are genetically predisposed. Women concerned about this should discuss their contraceptive options with their GP or a contraception specialist; switching to a preparation containing a less androgenic progestogen may be considered, though the evidence that this reliably improves hair loss is limited.

In line with NICE guideline NG23 (Menopause: diagnosis and management), HRT should be used at the lowest effective dose, with a review at approximately three months after starting and then annually thereafter. Duration of use should be guided by individual risk–benefit assessment; women may continue HRT for as long as the benefits outweigh the risks, and there is no arbitrary time limit. If you experience a suspected side effect from any hormonal treatment, please report it via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk).

When to Speak to a GP or Specialist About Hair Loss

See your GP promptly if you notice rapid shedding, scalp scarring or redness, signs of virilisation, or hair loss linked to starting or stopping a hormonal medication.

Hair loss can be distressing, and whilst it is not always a sign of serious underlying illness, there are circumstances in which prompt medical assessment is important. Many women delay seeking help due to embarrassment or a belief that hair loss is an inevitable part of ageing — but early intervention often leads to better outcomes.

You should speak to your GP if you notice:

• Sudden or rapid hair shedding over a period of weeks to months

• Significant thinning or bald patches on the scalp

• Scalp redness, pain, scaling, pustules, or areas that appear scarred or smooth — these features may suggest a scarring alopecia and warrant early specialist review

• Signs of virilisation (for example, deepening voice, increased body hair, severe acne), which require urgent investigation

• Hair loss accompanied by other symptoms such as fatigue, weight changes, irregular periods, or skin changes

• Hair loss that begins or worsens after starting or stopping a hormonal medication (including the contraceptive pill or HRT)

• A family history of significant hair loss and personal concern about early onset

Your GP will typically begin with a clinical history and examination, followed by targeted investigations based on the likely diagnosis. These may include:

• Full blood count (to check for anaemia)

• Thyroid function tests (TSH, free T4)

• Serum ferritin (iron stores)

• Hormonal profile (including testosterone, SHBG, LH, FSH, and prolactin where clinically indicated)

• DHEAS and 17-hydroxyprogesterone if hyperandrogenism is suspected

If an underlying condition such as PCOS or thyroid disease is identified, appropriate treatment of that condition often leads to improvement in hair loss over time. For women whose hair loss is not explained by routine investigations, or where there is diagnostic uncertainty, referral to a consultant dermatologist via NHS pathways is the appropriate next step. Dermatology is the relevant NHS medical specialty for hair loss assessment and management.

Private consultations with a trichologist are also available; however, trichology is not a statutorily regulated medical profession in the UK. If pursuing private trichology, it is advisable to check that the practitioner holds recognised professional membership (for example, with the Institute of Trichologists or the Trichological Society) and to ensure that any medical causes of hair loss have been excluded by a registered healthcare professional first.

NHS and NICE Guidance on Hormonal Hair Loss Management

NICE guideline NG23 guides HRT use for menopausal symptoms; topical minoxidil is the only MHRA-licensed treatment for female pattern hair loss, with anti-androgen therapies available off-label via specialists.

The management of hormonal hair loss in women in the UK is guided by a combination of NICE clinical guidelines, NHS clinical pathways, and specialist dermatology and primary care dermatology practice. NICE does not currently have a dedicated guideline specifically for female pattern hair loss, but relevant guidance is drawn from several sources, including NICE guideline NG23 on menopause and NICE guidance on PCOS management. The Primary Care Dermatology Society (PCDS) and the British Association of Dermatologists (BAD) also provide UK-relevant clinical guidance on female pattern hair loss and telogen effluvium.

For women experiencing hair loss in the context of the menopause, NICE guideline NG23 recommends that HRT should be considered where menopausal symptoms are affecting quality of life. Hair changes are not specifically listed as an indication in NG23, but skin and hair changes associated with oestrogen deficiency may form part of the overall symptom burden that informs the decision to offer HRT. The choice of progestogen within an HRT regimen should be made on an individual basis, taking into account the woman's medical history, preferences, and the available evidence; the British Menopause Society (BMS) and the Faculty of Sexual and Reproductive Healthcare (FSRH) provide further guidance on progestogen selection.

For androgenetic alopecia, treatment options are limited but may include:

• Minoxidil (topical): Available over the counter; the only MHRA-licensed topical treatment for female pattern hair loss in the UK. It works by prolonging the anagen phase and increasing follicle size. Refer to the product SmPC (available via the EMC) for full prescribing information.

• Anti-androgen therapies: Such as spironolactone or finasteride, which may be prescribed off-label by specialists in secondary care for women with confirmed androgen-driven hair loss. These are not licensed for hair loss in women in the UK. Important safety information: Both spironolactone and finasteride are teratogenic and must not be used during pregnancy. Women of childbearing potential must use effective contraception throughout treatment. This should be discussed in detail with the prescribing specialist before starting treatment.

• Addressing nutritional deficiencies: Correcting iron deficiency (low ferritin) is supported by UK guidance and is a priority where identified. The evidence for routine vitamin D supplementation specifically improving hair loss is mixed and not conclusively established; vitamin D testing and supplementation should follow standard UK clinical guidance rather than being pursued specifically for hair loss.

No hormonal treatment — including progesterone — is currently licensed in the UK specifically for the treatment of hair loss. Women should be cautious of unregulated supplements or online services offering hormonal treatments without appropriate clinical oversight. Always seek advice from a registered healthcare professional, and ensure any prescribed treatment is obtained through a regulated UK pharmacy or NHS service. Suspected side effects from any treatment should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Frequently Asked Questions